PRMT3 and neoplasm: With extended DEN-CCl4 treatment, deletion of Prmt3 significantly reduced tumor burden, as evidenced by liver/body weight ratio, tumor number, and tumor size, but did not affect the incidence of tumor formation at 26-week-old (Fig. 1B–D).